These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3315513)

  • 1. Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII.
    Scheen AJ; Henrivaux P; Jandrain B; Paolisso G; Lefèbvre PJ
    Diabetes Care; 1987; 10(5):567-72. PubMed ID: 3315513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.
    Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ
    Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.
    Scheen AJ; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetes Care; 1987; 10(6):707-11. PubMed ID: 3322727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overnight interruption of wearing insulin pump: substitution dose and injection site of insulin.
    Helve E; Pelkonen R; Koivisto VA
    Diabetes Care; 1986; 9(6):565-9. PubMed ID: 3542449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.
    Krzentowski G; Scheen A; Castillo M; Luyckx AS; Lefèbvre PJ
    Diabetologia; 1983 May; 24(5):314-8. PubMed ID: 6347779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
    Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
    Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
    Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
    Castillo MJ; Scheen AJ; Lefèbvre PJ
    J Clin Endocrinol Metab; 1996 May; 81(5):1975-8. PubMed ID: 8626867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Guerci B; Meyer L; Sallé A; Charrié A; Dousset B; Ziegler O; Drouin P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2673-8. PubMed ID: 10443658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic control in newly kidney transplanted insulin-dependent diabetics: improvement by insulin pump treatment (CSII).
    Schmitz O; Sorensen SS; Alberti KG; Orskov H; Hansen HE
    J Diabet Complications; 1987; 1(3):81-6. PubMed ID: 2969910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Montaña E; Fernández-Castañer M; Rosel P; Gómez JM; Vinzia C; Soler J
    Diabete Metab; 1990; 16(3):220-5. PubMed ID: 2210017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.
    Jimenez JT; Walford S; Home PD; Hanning I; Alberti KG
    Diabetologia; 1985 Oct; 28(10):728-33. PubMed ID: 3905470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
    Oskarsson PR; Lins PE; Backman L; Adamson UC
    Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nocturnal continuous subcutaneous insulin infusion--a therapeutic possibility in labile type I diabetes under exceptional conditions].
    Bruns W; Steinborn F; Menzel R; Staritz B; Bibergeil H
    Z Gesamte Inn Med; 1990 Mar; 45(6):154-8. PubMed ID: 2197828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.